CN100389781C - Use of pharmacy for feline ginseng volatile oil - Google Patents
Use of pharmacy for feline ginseng volatile oil Download PDFInfo
- Publication number
- CN100389781C CN100389781C CNB200610052004XA CN200610052004A CN100389781C CN 100389781 C CN100389781 C CN 100389781C CN B200610052004X A CNB200610052004X A CN B200610052004XA CN 200610052004 A CN200610052004 A CN 200610052004A CN 100389781 C CN100389781 C CN 100389781C
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- radix actinidiae
- actinidiae valvatae
- valvatae
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 52
- 241000208340 Araliaceae Species 0.000 title 1
- 241000282324 Felis Species 0.000 title 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title 1
- 235000003140 Panax quinquefolius Nutrition 0.000 title 1
- 235000008434 ginseng Nutrition 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 27
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 18
- 230000003385 bacteriostatic effect Effects 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 abstract description 11
- 241000219068 Actinidia Species 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 239000006187 pill Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 239000002245 particle Substances 0.000 abstract 1
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 16
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 10
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 229960004488 linolenic acid Drugs 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 9
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 8
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- -1 Palmic acid chemical compounds Chemical class 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- MBDOYVRWFFCFHM-UHFFFAOYSA-N 2-hexenal Chemical compound CCCC=CC=O MBDOYVRWFFCFHM-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 229940088601 alpha-terpineol Drugs 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 5
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 5
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 4
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 4
- DVWSXZIHSUZZKJ-UHFFFAOYSA-N 18:3n-3 Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OC DVWSXZIHSUZZKJ-UHFFFAOYSA-N 0.000 description 4
- MOQGCGNUWBPGTQ-UHFFFAOYSA-N 2,6,6-trimethyl-1-cyclohexene-1-carboxaldehyde Chemical compound CC1=C(C=O)C(C)(C)CCC1 MOQGCGNUWBPGTQ-UHFFFAOYSA-N 0.000 description 4
- IMKHDCBNRDRUEB-UHFFFAOYSA-N Dihydroactinidiolide Natural products C1CCC(C)(C)C2=CC(=O)OC21C IMKHDCBNRDRUEB-UHFFFAOYSA-N 0.000 description 4
- LSRNBGXEEKNZHN-UHFFFAOYSA-N Dihydronepetalactone Chemical compound O=C1OCC(C)C2C1C(C)CC2 LSRNBGXEEKNZHN-UHFFFAOYSA-N 0.000 description 4
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 4
- 239000005792 Geraniol Substances 0.000 description 4
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 4
- IMKHDCBNRDRUEB-LLVKDONJSA-N dihydroactinidiolide Chemical compound C1CCC(C)(C)C2=CC(=O)O[C@@]21C IMKHDCBNRDRUEB-LLVKDONJSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229940113087 geraniol Drugs 0.000 description 4
- FNAZRRHPUDJQCJ-UHFFFAOYSA-N henicosane Chemical compound CCCCCCCCCCCCCCCCCCCCC FNAZRRHPUDJQCJ-UHFFFAOYSA-N 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 229930007744 linalool Natural products 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- MBDOYVRWFFCFHM-SNAWJCMRSA-N 2-Hexenal Natural products CCC\C=C\C=O MBDOYVRWFFCFHM-SNAWJCMRSA-N 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- CBFCDTFDPHXCNY-UHFFFAOYSA-N icosane Chemical compound CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- DVWSXZIHSUZZKJ-YSTUJMKBSA-N methyl linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OC DVWSXZIHSUZZKJ-YSTUJMKBSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 238000001256 steam distillation Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 2
- CJPNOLIZCWDHJK-UHFFFAOYSA-N 2-Pentadecanone Chemical compound CCCCCCCCCCCCCC(C)=O CJPNOLIZCWDHJK-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- RZKSECIXORKHQS-UHFFFAOYSA-N Heptan-3-ol Chemical compound CCCCC(O)CC RZKSECIXORKHQS-UHFFFAOYSA-N 0.000 description 2
- LYEFRAMOOLOUKA-RBXMUDONSA-N Iridomyrmecin Chemical compound [C@@H]1([C@@H](C(=O)OC2)C)[C@H]2[C@@H](C)CC1 LYEFRAMOOLOUKA-RBXMUDONSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 2
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 2
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 2
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 235000000484 citronellol Nutrition 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- FYIKZVZDDDOFSA-UHFFFAOYSA-N dodeca-6,11-dien-1-ol Chemical compound OCCCCCC=CCCCC=C FYIKZVZDDDOFSA-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- LYEFRAMOOLOUKA-UHFFFAOYSA-N isoepiiridomyrmecin Natural products C1OC(=O)C(C)C2C1C(C)CC2 LYEFRAMOOLOUKA-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- XUDJZDNUVZHSKZ-UHFFFAOYSA-N methyl ester of tetracosanoic acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OC XUDJZDNUVZHSKZ-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- 238000009834 vaporization Methods 0.000 description 2
- 230000008016 vaporization Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- VIINAUVGZZLXGK-HCUGZAAXSA-N (2E)-3,7-dimethylocta-2,6-dien-1-ol 3,7-dimethylocta-2,6-dien-1-ol Chemical compound CC(C)=CCCC(C)=CCO.CC(C)=CCC\C(C)=C\CO VIINAUVGZZLXGK-HCUGZAAXSA-N 0.000 description 1
- ONYJRUXYOCZIAW-BLWKUPHCSA-N (2e,6e)-octa-2,6-dien-1-ol Chemical compound C\C=C\CC\C=C\CO ONYJRUXYOCZIAW-BLWKUPHCSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
- UFLHIIWVXFIJGU-ONEGZZNKSA-N (E)-3-Hexenol Natural products CC\C=C\CCO UFLHIIWVXFIJGU-ONEGZZNKSA-N 0.000 description 1
- GLZPCOQZEFWAFX-JXMROGBWSA-N (E)-Geraniol Chemical compound CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
- WUOACPNHFRMFPN-VIFPVBQESA-N (R)-(+)-alpha-terpineol Chemical compound CC1=CC[C@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-VIFPVBQESA-N 0.000 description 1
- 239000000267 (Z)-hex-3-en-1-ol Substances 0.000 description 1
- UFLHIIWVXFIJGU-ARJAWSKDSA-N (Z)-hex-3-en-1-ol Chemical compound CC\C=C/CCO UFLHIIWVXFIJGU-ARJAWSKDSA-N 0.000 description 1
- BOTWFXYSPFMFNR-HMMYKYKNSA-N (e)-3,7,11,15-tetramethylhexadec-2-en-1-ol Chemical compound CC(C)CCCC(C)CCCC(C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-HMMYKYKNSA-N 0.000 description 1
- 229930008411 3,7-dimethylocta-2,6-dien-1-ol Natural products 0.000 description 1
- PNJLLTZAEWRCRQ-UHFFFAOYSA-N 4-ethenyl-2-methoxyphenol Chemical compound COC1=CC(C=C)=CC=C1O.COC1=CC(C=C)=CC=C1O PNJLLTZAEWRCRQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000411138 Arthroderma otae ATCC 36299 Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- MWALFSGTYJQHSZ-UHFFFAOYSA-N CCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCC Chemical compound CCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCC MWALFSGTYJQHSZ-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 1
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000534473 Valvata Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- PGIQIBRWODQISW-UHFFFAOYSA-N dec-3-yn-2-ol Chemical compound CCCCCCC#CC(C)O PGIQIBRWODQISW-UHFFFAOYSA-N 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- OTWKHRIFRPCNIR-UHFFFAOYSA-N docosane Chemical compound CCCCCCCCCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCCCCCCCC OTWKHRIFRPCNIR-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- LXHHROBUZABRSD-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC.CCCCCCCCCCCC LXHHROBUZABRSD-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- JYYFMIOPGOFNPK-AGRJPVHOSA-N ethyl linolenate Chemical compound CCOC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC JYYFMIOPGOFNPK-AGRJPVHOSA-N 0.000 description 1
- JYYFMIOPGOFNPK-UHFFFAOYSA-N ethyl linolenate Natural products CCOC(=O)CCCCCCCC=CCC=CCC=CCC JYYFMIOPGOFNPK-UHFFFAOYSA-N 0.000 description 1
- 229940090028 ethyl linolenate Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- GXNDYZPMZKJDSS-UHFFFAOYSA-N hex-1-ene Chemical compound CCCCC=C.CCCCC=C GXNDYZPMZKJDSS-UHFFFAOYSA-N 0.000 description 1
- KVPRHHGZQGZFKR-UHFFFAOYSA-N hex-2-en-1-ol Chemical compound CCCC=CCO.CCCC=CCO KVPRHHGZQGZFKR-UHFFFAOYSA-N 0.000 description 1
- KVDORLFQOZGRPI-UHFFFAOYSA-N hex-3-en-1-ol Chemical compound C(CC=CCC)O.C(CC=CCC)O KVDORLFQOZGRPI-UHFFFAOYSA-N 0.000 description 1
- UFLHIIWVXFIJGU-UHFFFAOYSA-N hex-3-en-1-ol Natural products CCC=CCCO UFLHIIWVXFIJGU-UHFFFAOYSA-N 0.000 description 1
- HRFPRVYNMNOAQO-UHFFFAOYSA-N hexadec-3-yne Chemical compound CCCCCCCCCCCCC#CCC HRFPRVYNMNOAQO-UHFFFAOYSA-N 0.000 description 1
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Chemical group CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- SHPVOXFREBUEHB-UHFFFAOYSA-N oct-6-en-1-ol Chemical compound CC=CCCCCCO SHPVOXFREBUEHB-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RYTQKVZHGHLRCO-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC.CCCCCCCCCCCCCC RYTQKVZHGHLRCO-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An application of the volatile oil of volvate actinidia in preparing the antibacterial medicines in the form of injection, capsule, dripping pill, tablet, particle, etc is disclosed. Said volatile oil is prepared from the fresh leaves of volvate actinidia through conventional extracting.
Description
Technical field
The present invention relates to the purposes of Radix actinidiae valvatae leaf's volatile oil, especially the purposes in pharmacy.
Background technology
Along with human living standard's raising, the extensive application of antibiotics, chemicals causes some mushroom to develop immunity to drugs, and life has caused serious threat to human being's production for this.The countries in the world medical experts constantly are devoted to seek the control medicament that toxic and side effects is little, mushroom is difficult for developing immunity to drugs.China's Chinese herbal medicine resource is abundant, and high-efficiency low-toxicity is with low cost.Vast Chinese medicine worker has made a large amount of good tries to the activity of Chinese herbal medicine antibacterial and bacteriostatic, has accumulated many experiences.
The Radix actinidiae valvatae is the big seed Fructus actinidiae chinensis of Actinidiaceae actinidia Actinidia macrospermaC.F.Liang or to calyx Fructus actinidiae chinensis Actinidia.valvata Dunn.The former is commonly called as " pearls and jewels " in Chinese medicine, the latter is commonly called as " heroin ".Mainly be distributed in China East China and South China, concentrate on provinces such as Guangdong, Hunan, Hubei, Jiangxi, Zhejiang, Jiangsu, Anhui.Put down in writing according to the Chinese medicine dictionary: this flavour of a drug hardship, cold in nature, attach to the lung and stomach meridians; Rhizome is used as medicine; Has the effect that heat-clearing and toxic substances removing, expelling wind and removing dampness, detumescence go furuncle; Clinically be used for the treatment of diseases such as sores ulceration of skin abscess, leprosy, osteomyelitis, rheumatic arthralgia, leucorrhea abnormal, liver cirrhosis jaundice ascites, the treatment that also is used for pulmonary carcinoma and digestive tract tumor among the people.The Radix actinidiae valvatae is suppressing tumor growth, and improving the sign of life aspect has unique effect, through repeatedly practising, has formed the proved recipe based on Radix actinidiae valvatae's various treatment tumors gradually, causes the concern of Chinese medicine circle.Because the good efficacy of Radix actinidiae valvatae aspect antitumor raising immunity to such an extent as to other pharmacological action has been ignored greatly, all do not have relevant for the medicinal record of volatile oil of Radix actinidiae valvatae in pharmacopeia and the various book on Chinese herbal medicine.Up to the present, yet there are no bibliographical information about this traditional medicine volatile oil chemical constituent, pharmacological action and application thereof.Application to the Radix actinidiae valvatae, also only only limit to after its whole processing, make Chinese patent medicine jointly as one of polypharmaceutic raw material and other raw material, do not find as yet with Radix actinidiae valvatae be raw material particularly as single raw material process also/maybe with the extract that processes directly as the manufacture method and the manufactured goods thereof of drug use.
Cited literature 2:
1.. Qiu Baolin etc. Zhejiang flora (Volume Four). Zhejiang: Zhejiang science tech publishing house, 1993:177.
2.. the new medical college in Jiangsu. Chinese medicine dictionary (descending). Shanghai: Shanghai science tech publishing house, 1977:2205.
3.. Yao Gan, Wang Tieseng. the arrangement of East China Actinidia medicinal plants. Chinese crude drug, 1989,12 (2): 15.
4.. Zhejiang Department of Public Health. Zhejiang Province's Chinese medicine processing standard. Hangzhou: Zhejiang science tech publishing house, 1994:89.
5.. Jin Ruizhi, Wang Guoqiang. the Radix actinidiae valvatae treats the tympanites example and releases. Zhejiang Journal of Traditional Chinese Medicine, 1998,33 (1): 35.
6.. Ni Qinwu, Zhuge Gansu Province. the Study on Identification of Radix actinidiae valvatae and adulterant thereof. Zhejiang College Of Traditional Chinese Medicine journal, 1999,23 (5): 60.
7.. Zhou Xingzhao. Tang Fuan opinion pulmonary carcinoma card is controlled. Zhejiang College Of Traditional Chinese Medicine journal, 2000,24 (2): 45.
8.. next ordinary, Zhang Hongyan. Zhejiang area is commonly used Chinese medicine Radix actinidiae valvatae progress. Zhejiang College Of Traditional Chinese Medicine journal, 2002,26 (1): 77～78.
Summary of the invention
The object of the present invention is to provide the new purposes of Radix actinidiae valvatae leaf's active component volatile oil, i.e. purposes in pharmacy.
Characteristics of the present invention are the application of Radix actinidiae valvatae leaf's volatile oil in preparation antibacterial bacteriostatic medicine.
The present invention is specifically related to the new application of Radix actinidiae valvatae leaf's active component volatile oil in preparation antibacterial bacteriostatic folk prescription or compound medicine.
The present invention is a raw material with Radix actinidiae valvatae leaf's volatile oil, it can be developed to suitable antibacterial bacteriostatic pharmaceutical preparation as acceptable carrier or pharmaceutic adjuvant on active component and the pharmacopedics, as injection, capsule (soft capsule, hard capsule), drop pill, tablet, granule, powder, oral liquid etc.
In order to understand essence of the present invention better, with the external bacteriostatic activity research of volatile oil of Radix actinidiae valvatae and the result of acute toxicity testing its purposes in preparation antibacterial bacteriostatic medicine is described below.
One, external bacteriostatic experiment
1. experiment material and method
1.1 the bacterial strain experimental strain comprises two kinds of gram positive bacterias: gold-coloured staphylococci (Staphylococcus aureus ATCC 25923) and bacillus subtilis (Bacillus subtilis ATCC26633); Two kinds of gram negative bacterias: escherichia coli (Escherichia coli ATCC 25922) and bacillus pyocyaneus (Pseudomonas aeruginosa ATCC 27853); Three kinds of funguses: yeast (Candida albicans ATCC 10231), Aspergillus fumigatus (Aspergillus fumigatus ATCC 9142) and Sabouraudites lanosus (Microsporum canis ATCC 36299).The clinical disease performance of each strain sees Table 1.
The clinical disease performance of each strain of table 1
1.2 experimental technique adopts agar diffusion method of the paper that external bacteriostatic activity is carried out preliminary survey.Adopt micro-dilution method measure minimal inhibitory concentration (minimum inhibitory concentration, MIC) and minimal bactericidal concentration (minimum bactericidal or fungicidal concentration, MBC/MFC).
2. experimental result
The results are shown in Table 2, table 3.
Volatile oil of Radix actinidiae valvatae has certain inhibitory action to gram positive bacteria, gram negative bacteria there is strong inhibitory action (except that this general drug resistance strain of bacillus pyocyaneus), minimal inhibitory concentration MIC is 0.78～25.50 μ l/ml, minimal bactericidal concentration 1.56～50.0 μ l/ml; In the test of fungus, volatile oil of Radix actinidiae valvatae shows stronger inhibition activity, and minimal inhibitory concentration MIC is 0.78～1.56 μ l/ml, minimal bactericidal concentration 0.78～3.12 μ l/ml.
The external bacteriostatic activity preliminary survey (paper disk method) of table 2 volatile oil of Radix actinidiae valvatae
A, b
aAntibacterial circle diameter 7～13mm represents faint activity; Antibacterial circle diameter 〉=14mm represents strong active
b-expression does not have activity; Nd represents not detect.
Minimal inhibitory concentration of table 3 volatile oil of Radix actinidiae valvatae (MIC) and minimal bactericidal concentration (MBC/MFC)
(micro-dilution method)
According to the report of volatile oil of Radix actinidiae valvatae chemical composition analysis with relevant pharmacology document, we find: the linalool in the volatile oil of Radix actinidiae valvatae has obvious antibacterial activity, and analgesia, spasmolytic, antileukemie effect are arranged; The 2-hexenoic aldehyde can be as the wound disinfection agent, tool antibacterial bacteriostatic activity; In addition, chemical compounds such as phytol, alpha-terpineol, geraniol and Palmic acid also have certain bacteriostatic activity.
Two, acute toxicity testing
1. experiment material and method
1.1 animal Kunming kind white mice 18～22g, male and female half and half, the quarantine back is standby.
1.2 the experimental technique mice is divided into 5 dosage groups by the body weight equilibrium, 20 every group.Fasting be can't help water 12 hours before the experiment, according to the preliminary experiment result, each is organized dosage and is respectively 2.00ml/kg, 2.56ml/kg, 3.20ml/kg, 4.00ml/kg, 5.00ml/kg, volatile oil of Radix actinidiae valvatae is diluted to mouse stomach with salad oil, observe 4h, 24h, each observation of 48h, 72h after the administration continuously once.72h record white mice toxic reaction and death toll are with the half lethal dose LD of improvement karber's method calculating white mice
50And 95% confidence interval.
2. experimental result
Result such as table 4.After measured, LD
50Value is 3.27ml/kg, the 95% credible 3.04～3.54ml/kg (P＞0.05) that is limited to.According to mensuration, 1ml volatile oil heavily is 1.17259 g, so LD
50Value is 3834mg/kg, the 95% credible 3565～4150mg/kg that is limited to; Press acute toxicity grading criteria and judge the true border of this sample non-toxic type.
Table 4 volatile oil of Radix actinidiae valvatae is to the influence of acute toxicity test in mice mortality rate
| Dosage (ml/kg) | Total mice | The 72h death toll | Mortality rate (%) |
| 5.00 | 20 | 20 | 100 |
| 4.00 | 20 | 15 | 75 |
| 3.20 | 20 | 10 | 50 |
| 2.56 | 20 | 3 | 15 |
| 2.00 | 20 | 0 | 0 |
In sum, volatile oil of Radix actinidiae valvatae has good efficacy in external antibacterial especially the inhibition aspect the fungus, and toxic and side effects is little, and the excellent development application prospect is arranged.
The used raw material of volatile oil of Radix actinidiae valvatae of the present invention is the fresh leaf of Radix actinidiae valvatae, but not rhizome, this will alleviate the insufficient phenomenon of Radix actinidiae valvatae's raw medicinal herbs supply to a certain extent, improve Radix actinidiae valvatae's effective rate of utilization.Method technology of the present invention is simple, meets the requirement of Chinese Pharmacopoeia, need not special installation.Through pharmacological research, find that it has tangible bacteriostatic activity, especially to the inhibitory action (through experiment confirm, volatile oil of Radix actinidiae valvatae antibacterial minimal inhibitory concentration MIC is 0.78～25.50 μ l/ml, and fungus minimal inhibitory concentration MIC is 0.78～1.56 μ l/ml) of fungus.And volatile oil of Radix actinidiae valvatae has the little advantage of toxic and side effects, the excellent development application prospect is arranged, can with other medicinal herb components compatibilities, or separately directly as medicine, be developed further into effective antibacterial new drug, make Radix actinidiae valvatae's medicinal ingredient be fully utilized, thereby filled up the blank that China's Chinese herbal medicine utilizes, have practical value.
The method that volatile oil of Radix actinidiae valvatae among the present invention adopts common steam distillation, solvent extraction method or supercritical extraction etc. to be suitable for suitability for industrialized production is prepared.The volatile oil of Radix actinidiae valvatae that obtains is faint yellow, mainly contain linalool (Linalool), 1,2-dimethyl-2,3-indoline (1,2-dimethyl, Lindoline), methyl linolenate (Linolenic acid, methylester), phytol (Phytol), linolenic acid (α-Linolenic acid), 2-hexenoic aldehyde (2-Hexenal), alpha-terpineol (α-Terpineol), geraniol ((E)-3,7-dimethyl--2,6-Octadien-l-ol) and Palmic acid chemical compounds such as (n-Hexadecanoic acid).Oil content is 0.10～0.25%, and promptly every 100g crude drug contains volatile oil 0.1～0.25g.
Above-mentioned steam distillation separates volatile oil by oil water separator, the steps include: to calculate by weight, take by weighing 0.1～20 part of Radix actinidiae valvatae leaf, add 0.5～200 part in water, vapor distillation 3～5 hours, temperature is controlled at 80～105 ℃ (distillation temperature in early stage can be provided with highlyer, and the later stage boils for a short time as long as keep), carries out oil-water separation; With oil water separator separate moisture volatile oil of Radix actinidiae valvatae; After the extracted with diethyl ether, water is removed in lyophilization (20 ℃ of following lyophilizations are more than 24 hours) or anhydrous sodium sulfate drying (more than 24 hours), filtration, concentrates and obtains volatile oil of Radix actinidiae valvatae.
Above-mentioned solvent extraction method, the steps include: to get 0.1～20 part of Radix actinidiae valvatae leaf, add organic solvent-normal hexane or 0.6～120 part of weight portion of cyclohexane extraction, carry out reflux, extract,, temperature is controlled at 60～70 ℃, refluxes 2～3 hours, when treating that the backflow temperature is reduced to room temperature, emit backflow, reclaim organic solvent, can obtain the volatile oil crude product; Add dehydrated alcohol 0.01～0.05 weight portion, fully mix, place in-20 ℃ of refrigerator-freezers and place more than 24 hours, turbid solution is filtered wax removing with the volatile oil crude product; Continue to place in the refrigerator-freezer and repeat wax removing process, clarify up to liquid; The ethanol liquid that will contain volatile oil concentrates, and promptly gets volatile oil of Radix actinidiae valvatae.
Above-mentioned supercritical extraction the steps include: to get the Radix actinidiae valvatae leaf and adds extraction kettle, extraction kettle pressure 10～50Mpa, and 20～70 ℃ of temperature are carried out supercritical CO
2Extraction, the extraction time is 0.5～15 hour, the CO that comes out from extraction kettle
2Enter piece-rate system, 30～50 ℃ of flash trapping stage temperature, pressure 10～15Mpa; 20～40 ℃ of secondary separation temperatures, pressure 4～7Mpa obtains volatile oil of Radix actinidiae valvatae, CO
2Flow velocity is 15～25 liters/h, the CO that separates
2Recycling with refrigeration system pressurization back after filtration again.
The specific embodiment
Following example is in order to further specifying the present invention, but do not limit the scope of the invention thus.
Embodiment 1:
Get the bright leaf 100g of Radix actinidiae valvatae, add 10 times of water gagings, vapor distillation 5 hours; Separate moisture volatile oil with oil water separator; Ether spends the night with anhydrous sodium sulfate drying after repeatedly extracting on a small quantity, and filtering and concentrating obtains volatile oil of Radix actinidiae valvatae.Volatile oil is light yellow transparent liquid sample, and special fragrant is arranged, and oil yield is 0.10%, and promptly 100g Radix actinidiae valvatae aquatic foods contain volatile oil 0.10g.
Volatile oil carries out the GC-MS analysis, result such as table 5 after adding a small amount of anhydrous alcohol solution.Chromatographic condition: quartz capillary column HP-5MS (30m * 0.25mm * 0.25 μ m), carrier gas is a helium, post flow 1ml/min.Temperature of vaporization chamber: 260 ℃, heating schedule is for to be warming up to 260 ℃ since 50 ℃ with 10 ℃/min; Mass spectrum condition: EI ionization source, ionizing energy 70eV, 230 ℃ of ion source temperatures, sweep limits: 30～500amu, sample size 1.0 μ L, split ratio 10: 1.
Table 5 volatile oil of Radix actinidiae valvatae component analysis result (steam distillation)
| The chemical compound title | Relative amount (%) | The chemical compound title | Relative amount (%) |
| 2-Hexenal 2-hexenoic aldehyde | 0.75 | Contain the N heterocyclic compound | 14.38 |
| β-Cyclocitral β-cyclocitral | 0.34 | 6,10,14-trimethyl, 2-Pentadecanone 6,10,14-trimethyl-2-15 ketone | 0.16 |
| The Nonanal aldehyde C-9 | 0.43 | Hexadecanoic acid, the methylester methyl hexadecanoate | 0.52 |
| β-Linalool β-linalool | 48.14 | Hexadecanoic acid Palmic acid | 1.32 |
| The Decanal capraldehyde | 0.12 | Linoleic acid, the methylester methyl linoleate | 0.67 |
| α-Terpinenol α-terpinol | 0.96 | Linolenic acid, the methylester methyl linolenate | 6.57 |
| 3, the 7-dimethyl-2-Octen-1-ol citronellol | 0.73 | The Phytol phytol | 5.29 |
| 3,7-dimethyl-2,6-Octadien-1-ol geraniol | 1.59 | Linolenic acid, the ethylester ethyl linolenate | 0.29 |
| 1,2-dimethyl, Lindoline 1,2-dimethyl-2,3-indoline | 7.94 | The Eicosane AI3-28404 | 0.34 |
| 4-ethenyl-2-methoxy, Phenol 4-vinyl-2-methoxyphenol | 0.61 | α-Linolenic acid alpha-linolenic acid | 0.48 |
| β-Lonene 4-(2,6,6-trimethyl-1-cyclohexene)-3-cyclobutenyl-2-ketone | 0.16 | The Heneicosane Heneicosane | 0.82 |
| The Dihydronepetalactone dihydronepetalactoneand | 0.79 | The Docosane n-docosane | 0.59 |
| The Dihydroactinidiolide dihydroactinidiolide | 0.76 | Tetracosanoid acid, methylester tetracosanoic acid methyl ester | 0.08 |
Embodiment 2:
Get Radix actinidiae valvatae's fresh leaf 100g, add normal hexane 600ml, refluxed 2 hours; Oil-containing normal hexane concentrating under reduced pressure adds a small amount of dehydrated alcohol 10ml thermosol, places and places 24 hours low temperature wax removing in-20 ℃ of refrigerator-freezers, filters; The wax removing step repeats 3 times, clarifies up to fluid; Filtered residue is molten with dehydrated alcohol slight fever again, and low temperature is placed and filtered, last merging filtrate; Concentrate oil-containing ethanol liquid, filtering and concentrating obtains volatile oil of Radix actinidiae valvatae.Volatile oil is light yellow transparent liquid sample, and special fragrant is arranged, and oil yield is 0.20%, and promptly the bright leaf of 100g Radix actinidiae valvatae contains volatile oil 0.20g.
Volatile oil carries out the GC-MS analysis, result such as table 6 after adding a small amount of anhydrous alcohol solution.Chromatographic condition: quartz capillary column HP-5MS (30m * 0.25mm * 0.25 μ m), carrier gas is a helium, post flow 1mL/min.Temperature of vaporization chamber: 260 ℃, heating schedule is for to be warming up to 260 ℃ since 50 ℃ with 10 ℃/min; Mass spectrum condition: EI ionization source, ionizing energy 70eV, 230 ℃ of ion source temperatures, sweep limits: 30～500amu, sample size 1.0 μ L, split ratio 10: 1.
Table 6 volatile oil of Radix actinidiae valvatae component analysis result (solvent extraction method)
| The chemical compound title | Relative amount (%) | The chemical compound title | Relative amount (%) |
| 2-Hexenal 2-hexenoic aldehyde | 0.01 | Dodeca-1,6-dien-12-ol, 6,10-dimethyl, 6,10-dimethyl-1,6-12 diene-12-alcohol (different) | 1.51 |
| 3-Hexen-1-ol 3-hexenol | 0.26 | The Tetradecane n-tetradecane | 0.16 |
| 2-Hexen-1-ol 2-hexenol | 0.06 | The Dihydronepetalactone dihydronepetalactoneand | 1.97 |
| 1-Hexene 1-hexene | 0.02 | The Iridomyrmecin iridomyrmecin | 0.40 |
| 3-Hexen-1-ol, acetate acetic acid 3-hexene ester | 0.03 | The Dihydroactinidiolide dihydroactinidiolide | 0.18 |
| 3-methyl, 3-Heptanol 3-methyl-3-enanthol | 0.05 | The Hexadecane Pentadecane | 0.08 |
| Benzyl Alcohol benzyl alcohol | 0.31 | 3,7,11,15-Tetramethyl-2-Hexadecen-1-ol 3,7,11,15-tetramethyl-2-hexadecylene alcohol | 0.24 |
| β-Linalool β-linalool | 0.93 | 2-Pentadecanone, 6,10,14-trimethyl 6,10,14-trimethyl-2-15 ketone | 0.04 |
| 3-Decyn-2-ol 2-hydroxyl-3-decine | 0.02 | N-Hexadecanoic acid Palmic acid | 3.46 |
| Phenylethyl Alcohol phenethanol | 0.04 | Linolenic acid, the methylester methyl linolenate | 0.31 |
| The Dodecane n-dodecane | 0.24 | The Phytol phytol | 1.64 |
| Cis-α-Terpineol alpha-terpineol | 0.18 | α-Linolenic acid alpha-linolenic acid | 60.97 |
| (R)-, 3,7-dimethyl-, 6-Octen-l-ol 3,7-dimethyl-6-matsutake alcohol (citronellol) | 0.13 | The Spinacen Squalene | 6.04 |
| 2,6-Octadien-1-ol, 3,7-dimethyl-, 3,7-dimethyl-2,6-octadienol (geraniol) | 0.52 | Vitamin E vitamin E | 2.05 |
| 1,2-dimethyl, Lindoline 1,2-dimethyl-2,3-indoline | 0.23 | τ-Sitosterol τ-sitosterol | 1.40 |
| Dodeca-1,6-dien-12-ol, 6,10-dimethyl, 6,10-dimethyl-1,6-12 diene-12-alcohol | 6.30 | α-Tocopherol vitamin E | 1.78 |
| 3-Hexadecyne 3-hexadecine | 1.41 | β-Amyrin β-Amyrin | 0.84 |
Example 3:
Get the Radix actinidiae valvatae leaf and add 350g input extraction kettle, extraction kettle pressure 20Mpa, 30 ℃ of temperature; 30 ℃ of flash trapping stage temperature, pressure 10Mpa; 20 ℃ of secondary separation temperatures, pressure 4Mpa.Supercritical fluid static immersing raw material 1 hour, equipment are stablized laggard action attitude extraction, collect product by receptor.Get volatile oil of Radix actinidiae valvatae 0.87g at last, volatile oil is light yellow transparent liquid sample, and special fragrant is arranged, and oil yield is 0.25%, and promptly the bright leaf of 100g Radix actinidiae valvatae contains volatile oil 0.25g.
Volatile oil carries out the GC-MS analysis after adding a small amount of anhydrous alcohol solution, the result is similar to example 1,2, find to contain linalool, 1 at least, 2-dimethyl-2, compositions such as 3-indoline, methyl linolenate, phytol, linolenic acid, 2-hexenoic aldehyde, alpha-terpineol, geraniol and Palmic acid.
The partial reference document that the present invention relates to:
(1)NCCLS-National Committee for Clinical Laboratory Standards，2001.Performancestandards for antimicrobial susceptibility testing：eleventh informational supplement.Document M100-S11.National Committee for Clinical Laboratory Standard，Wayne，PA，USA.
(2)Peana，A.T.，D’Aquila，P.S.，Chessa，M.L，Moretti，M.D.，Serra，G，Pippia，P.，2003.(-)-Linalool produces antinociception in two experimental models of pain.European Journal of Pharmacology 460，37-41.
(3)Chiang，L.C.，Chiang，W.，Chang，M.Y.，Ng，L.T.，Lin，C.C.，2003.Antileukemicactivity of selected natural products in Taiwan.American Journal of Chinese Medicine31，37-46.
(4)Chiang，L.C.，Ng，L.T.，Chiang，W.，Chang，M.Y.，Lin，C.C.，2003.Immunomodulatory activities of flavonoids，monoterpenoids，triterpenoids，iridoidglycosides and phenolic compounds of Plantago species.Planta Medica 69，600-604.
(5)Lis-Balchin，M.，Hart，S.，1999.Studies on the mode of action of the essential oil oflavender(Lavandula angustifolia P. Miller).Phytotherapy Research 13，540-542.
(6)Schutz，S.，Weissbecker，B.，Klein，A.，Hummel，H.E.，1997.Host plant selection ofthe Colorado potato beetle as influenced by damage induced volatiles of the potato plant.Natur-wissenschaften 84，212-217.
(7)Findlay，J.A.，Patil，A.D.，1984.Antibacterial constituents of the diatom Naviculadelognei.J Nat Prod 47(5)，815-818.
(8)Christina，K.，Martin，K.，Alison，R.，2005.Chemical composition and antibacterialactivity of the essential oil and the Gum of Pistacia lentiscus Var.chia.J.Agric.FoodChem.53(20)，7681-7685.
(9)Terry，L.A.，Joyce，D.C.，Khambay，B.P.S.，2003.Antifungal compounds in Geraldtonwaxflower tissues.Australasian Plant Pathology 32(3)，41-420.
(10)Yff,B.T.，Lindsey，K.L.，Taylor，M.B.，Erasmus，D.G.，Jager，A.K，2002.Thepharmacolofical screening of Pentanisia prunelloides and the isolation of the antibacterialcompound palmitic acid.J Ethnopharmacol 79(1)，101-107.
Claims (1)
1. the application of Radix actinidiae valvatae leaf's volatile oil in preparation antibacterial bacteriostatic medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610052004XA CN100389781C (en) | 2006-06-16 | 2006-06-16 | Use of pharmacy for feline ginseng volatile oil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610052004XA CN100389781C (en) | 2006-06-16 | 2006-06-16 | Use of pharmacy for feline ginseng volatile oil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1895305A CN1895305A (en) | 2007-01-17 |
| CN100389781C true CN100389781C (en) | 2008-05-28 |
Family
ID=37608043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200610052004XA Expired - Fee Related CN100389781C (en) | 2006-06-16 | 2006-06-16 | Use of pharmacy for feline ginseng volatile oil |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100389781C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101584718B (en) * | 2008-05-19 | 2012-02-22 | 中国人民解放军第二军医大学 | Antisepalous kiwi fruit leaf extractive as well as preparation method and application thereof |
| EP2575452B1 (en) * | 2010-05-23 | 2018-12-19 | Takasago International Corporation | Antimicrobial compositions |
| CN110946848A (en) * | 2018-09-27 | 2020-04-03 | 东北师范大学 | Compound bactericide with broad-spectrum bactericidal effect |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1242203A (en) * | 1998-07-21 | 2000-01-26 | 邢炳荣 | Pure traditional Chinese medicine concentrated capsule for treating hepatitis B |
-
2006
- 2006-06-16 CN CNB200610052004XA patent/CN100389781C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1242203A (en) * | 1998-07-21 | 2000-01-26 | 邢炳荣 | Pure traditional Chinese medicine concentrated capsule for treating hepatitis B |
Non-Patent Citations (2)
| Title |
|---|
| 浙江地区习用中药猫人参研究进展. 来平凡等.浙江中医学院学报，第26卷第1期. 2006 |
| 浙江地区习用中药猫人参研究进展. 来平凡等.浙江中医学院学报，第26卷第1期. 2006 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1895305A (en) | 2007-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Karkanis et al. | Phytochemical composition, health effects, and crop management of liquorice (Glycyrrhiza glabra L.): Α medicinal plant | |
| Tagne et al. | Tithonia diversifolia (Hemsl.) A. Gray as a medicinal plant: A comprehensive review of its ethnopharmacology, phytochemistry, pharmacotoxicology and clinical relevance | |
| Zahidin et al. | A review of Acalypha indica L.(Euphorbiaceae) as traditional medicinal plant and its therapeutic potential | |
| Al-Snafi | Medical importance of Anthemis nobilis (Chamaemelum nobile)-a review | |
| Bozorgi et al. | Five Pistacia species (P. vera, P. atlantica, P. terebinthus, P. khinjuk, and P. lentiscus): a review of their traditional uses, phytochemistry, and pharmacology | |
| Ganesh et al. | Phytochemical analysis of Acanthus ilicifolius and Avicennia officinalis by GC-MS | |
| Gangwar et al. | Mallotus philippinensis Muell. Arg (Euphorbiaceae): ethnopharmacology and phytochemistry review | |
| Zeb et al. | Pharmacology, taxonomy and phytochemistry of the genus Artemisia specifically from Pakistan: a comprehensive review | |
| Ibrahim et al. | Pharmacognostic and phytochemical analysis of Commelina benghalensis L. | |
| Okhale et al. | Phytochemicaland proximate analyses and thin layer chromatography fingerprinting of the aerial part of Chenopodium ambrosioides Linn.(Chenopodiaceae) | |
| Bhandari et al. | 1, 8-Cineole: A predominant component in the essential oil of large cardamom (Amomum subulatum Roxb.) | |
| Kim et al. | The chemical composition and biological activities of essential oil from Korean native thyme Bak-Ri-Hyang (Thymus quinquecostatus Celak.) | |
| Aeganathan et al. | Anti-oxidant, antimicrobial evaluation and GC-MS analysis of Cyperus rotundus L. rhizomes chloroform fraction | |
| Kong et al. | The traditional herb Polygonum hydropiper from China: A comprehensive review on phytochemistry, pharmacological activities and applications | |
| Khouchlaa et al. | Traditional uses, bioactive compounds, and pharmacological investigations of Calendula arvensis L.: A Comprehensive review | |
| Kopyt’ko et al. | Uses, chemical composition, and standardization of plant raw material and medicinal substances from plants of the genus Asarum L. | |
| Vairinhos et al. | Essential oils of spontaneous species of the genus Lavandula from Portugal: a brief review | |
| CN100389781C (en) | Use of pharmacy for feline ginseng volatile oil | |
| Mishra et al. | Andrographolide content in Madhya Pradesh, India | |
| Dash | Phytochemical screening and pharmacological investigations on Hedychium coronarium | |
| Jabiullah et al. | Tinospora cordifolia: A medicinal plant: A review | |
| Kumar et al. | Phytochemistry of plants of genus Ocimum | |
| Gautam et al. | A brief study on phytochemical compounds present in Coccinia cordifolia for their medicinal, pharmacological and industrial applications | |
| Hewageegana et al. | A comparison of the physico-chemical and phytochemical parameters of glands/hairs of fruits and leaves of Mallotus philippensis (Lam.) Muell. Arg. grown in Sri Lanka | |
| Velaga et al. | Phytochemical analysis and immuno-modulatory effect of Moringa oleifera flowers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080528 |